Chemodenervation for facial dystonias and wrinkles

Current Opinion in Ophthalmology

Volumn 14, Issue 5, 2003, Pages 241-245

  Harrison, Andrew R ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Botulinum toxins; Chemodenervation; Facial spasms; Facial wrinkles

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; DOXORUBICIN; MONOCLONAL ANTIBODY; RICIN ANTIBODY;

BLEPHAROSPASM; CLINICAL TRIAL; DENERVATION; DIPLOPIA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; ECTROPION; ENTROPION; ERYTHEMA; EYELID MOVEMENT; FACE MUSCLE; FACE WRINKLING; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HEMIFACIAL SPASM; HUMAN; INJECTION SITE; LAGOPHTHALMOS; LETHAL DOSE; LONG TERM CARE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PRURITUS; PTOSIS; REVIEW; SIDE EFFECT; SKIN BRUISING; SKIN EDEMA; SKIN MANIFESTATION; SKIN ULCER; TREATMENT OUTCOME;

BOTULINUM TOXINS; COSMETIC TECHNIQUES; DYSTONIA; FACIAL MUSCLES; HUMANS; SKIN AGING; SYMPATHECTOMY, CHEMICAL;

EID: 0141838927     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-200310000-00003     Document Type: Review

References (46)

1. Scott AB, Rosenbaum A, Collins CC: Pharmacologic weakening of the extraocular muscles. Invest Ophthalmol 1973, 12:924-927.
2. Scott AB: Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980, 87:1044-1049.
3. Scott AB, Kennedy EG, Stubbs HA: Botulinum toxin as a treatment for blepharospasm. Arch Ophthalmol 1985, 103:347-350.
4. Tsoy EA, Buckley EG, Dutton JJ: Treatment of blepharospasm with botulinum toxin. Am J Ophthalmol 1985, 99:542-546.
5. Jancovic J, Orman J: Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987, 37:616-623.
6. Savino PJ, Sergott RC, Bosley TM, et al.: Hemifacial spasm treated with botulinum A toxin. Arch Ophthalmol 1985, 103:1305-1306.
7. Mauriello JA: Blepharospasm, meige syndrome and hemifacial spasm: treatment with botulinum toxin. Neurology 1985, 35:1499-1500.
8. Anderson RL, Patel BC, Holds JB, et al.: Blepharospasm: past, present and future. Ophthal Plast Reconstr Surg 1998, 14:305-317.
9. Gonnering RS: Treatment of hemifacial spasm with botulinum A toxin: results and rationale. Ophthal Plast Reconstr Surg 1986, 2:143-146.
10. Dutton JJ, Buckley EG: Longterm results and complications of botulinum toxin in the treatment of blepharospasm. Ophthalmology 1988, 95:1529-1534.
11. Dutton JJ: Botulinum-A toxin in the treatment of craniocervical muscle spasms: mic Short- and long-term, local and systemic effects. Surv Ophthalmol 1996, 41:51-65.
12. Matarasso A, Deva AK, et al.: Botulinum toxin. Plast Reconstr Surg 2002, 109:1191-1197.
13. Carruthers J, Carruthers A: Treatment of glabellar frown lines with C. Botulinum toxin A exotoxin. J Dermatol Surg Oncol 1992, 18:17.
14. Cather JC, Cather JC, Menter A: Update on botulinum toxin for facial aesthetics. Dermatol Clin 2002, 20:749-761.
15. Foster JA, Wulc AE, Holck DEE: Cosmetic indications for botulinum toxin. Semin Ophthalmol 1998, 13:142-148.
16. Carruthers J, Carruthers A: Botulinum toxin (Botox) chemodenervation for facial rejuvenation. Facial Plast Surg Clin of N Am 2001, 9:197-204.
17. Lamanna C: The most poisonous poison. Science 1959, 130:763-772.
18. Huang W, Foster JA, Rogachefsky AS: Pharmacology of botulinum toxin. J Am Acad Dermatol 2000, 43:249-259.
19. Koriazova LK, Montal M: Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol 2002, 10:13-18.
20. Klein AW: Dilution and storage of botulinum toxin. Dermatol Surg 1998, 24:1179.
21. Lowe NJ: Botulinum toxin type A for facial rejuvenation: United States and United Kingdom Perspectives. Dermatol Surg 1998, 24:1216.
22. Schantz EJ, Johnson EA: Dose standardization of botulinum toxin. Lancet 1990, 335:421.
23. Linder JS, Edmonson BC, Laquis SJ, et al.: Skin cooling before periocular botulinum toxin A injection. Ophthalmic Plast Reconstr Surg 2002, 18:441-442. Skin cooling prior to botulinum toxin injections significantly decreases the pain score in these patients.
24. Soylev MF, Kocak N, Kuvaki B, et al.: Anesthesia with EMLA cream for botulinum A toxin injection into eyelids. Ophthalmologica 2002, 216:355-358. Percutaneous anesthesia produced by EMLA cream significantly reduced the pain score of botulinum toxin injections in patients with facial dyskinesis.
25. Wirtschafter JD: Clinical doxorubicin chemomyectomy: an experimental treatment for benign essential blepharospasm and hemifacial spasm. Ophthalmology 1991, 98:357-366.
26. Wirtschafter JD, McLoon LK: Long-term efficacy of local doxorubicin chemomyectomy in patients with blepharospasm and hemifacial spasm. Ophthalmology 1998, 105:342-346.
27. McLoon LK, Wirtschafter JD: Doxil-induced chemomyectomy: effectiveness for permanent removal of orbiculris oculi muscle in monkey eyelid. Invest Ophthalmol Vis Sci 2001,42:1254-1257.
28. Wirtschafter JD: Doxil Chemomyectomy: 2 year results of Phase I clinical trial. J Neuro-ophth 2002, 22:186-187.
29. Christiansen SP, Becker BA, Iaizzo PA, et al.: Extraocular muscle force generation after ricin-mAb35 injection: implications for strabismus treatment. J AAPOS 2003, 7:1-6. Injection of ricin-mAb35 results in sustained weakness in extraocular muscle.
30. Christiansen SP, Peterson D, To T, et al.: Long-term effects of ricin-mAb 35 on extraocular muscles of rabbits: potential treatment for strabismus. Invest Ophthalmol Vis Sci 2002, 43:679-685.
31. Christiansen S, Sandnas A, Prill R, et al.: Acute effects of the skeletal muscle-specific immunotoxin, ricin-mAb 35, on extraocular muscles of rabbits. Invest Ophthalmol Vis Sci 2000, 41:3402-3409.
32. Hott JS, Dalakas MC, Sung C, et al.: Skeletal muscle-specific immunotoxin for the treatment of focal muscle spasm. Neurology 1998, 50:485-491.
33. Cakmur R, Ozturk V, Uzunel F, et al.: Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neurol 2002, 249:64-68.
34. Defazio G, Abbruzzese G, Girlanda P, et al.: Botulinum Toxin A treatment for primary hemifacial spasm: a ten year multicenter study. Arch Neurol 2002, 59:418-420. The effectiveness of botulinum toxin injections in the treatment of hemifacial spasm is sustained over a 10-year treatment period. The rate of local side effects diminished over the same time period.
35. Ozsoy Z, Aydm G, Genc B: Two-plane injection of botulinum toxin for the treatment of glabellar frown lines. Plast Reconstr Surg 2002, 110:371.
36. Carruthers JA, Lowe NJ, Menter MA, et al.: A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002, 46:840. Botulinum toxin A injections were effective in reducing glabellar line severity as compared to controls injected with placebo.
37. Heckmann M, Schon-Hupka G: Quantification of the efficacy of botulinum toxin type A by digital image analysis. J Am Acad Dermatol 2001, 45:508.
38. Sadick NS: Botulinum toxin type B for glabellar wrinkles: a prospective open-label response study. Dermatol Surg 2002, 28:817-821. Injections of botulinum toxin B are efficacious in the treatment of glabellar wrinkles. The mean duration of effect is 8 weeks.
39. Ramirez AL, Reeck J, Maas CS: Preliminary experience with botulinum toxin type B in hyperkinetic facial lines. Plast Reconstr Surg 2002, 109:2154-2155.
40. Ramirez AL, Reeck J, Maas CS: Botulinum toxin type B(Myobloc) in the management of hyperkinetic facial lines. Otolaryngol Head Neck Surg 2002, 126:459-467.
41. Matarasso SL, Matarasso A: Treatment guidelines for botulinum toxin type A for the periocular region and a report on partial upper lip ptosis following injections to the lateral canthal rhytids. Plast Reconstr Surg 2001, 108:208-217.
42. Lowe NJ, Lask G, Yamauchi P, et al.: Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet. J Am Acad Dermatol 2002, 47:834-840. Botulinum toxin A injections are safe and effective for the treatment of crow's feet. There is no clear dose-response relationship.
43. Flynn TC, Carruthers JA, Carruthers JA: Botulinum-A toxin treatment of the lower eyelid improves infraorbital rhytides and widens the eye. Dermatol Surg 2001, 27:703-708.
44. Huang W, Rogachefsky AS, Foster JA: Browlift with botulinum toxin. Dermatol Surg 2000, 26:55-60.
45. Huigol SC, Carruthers A, Carruthers JDA: Raising eyebrows with botulinum toxin. Dermatol Surg 2000, 25:373-376.
46. Sposito MMM: New Indications for botulinum toxin type A in cosmetics: mouth and neck. Plast Reconstr Surg 2002, 110:601-611. Botulinum toxin A injections are effective in treating mouth and neck wrinkles.